文献速递肿瘤 PET/CT放射性药物与辐射防护

成纤维细胞活化蛋白特异性PET/CT在纤维性间质性肺病与肺癌中的翻译探索研究

Fibroblast Activation Protein-Specific PET/CT Imaging in Fibrotic Interstitial Lung Diseases and Lung Cancer: A Translational Exploratory Study.
PubMed 文献 · J Nucl Med · 2021-07-16

该探索性研究对15例纤维性间质性肺病(fILD)并疑似肺癌(LC)患者行68Ga-FAPI-46 PET/CT静态与动态显像,fILD病灶与LC均呈明显高摄取且靶本比高,摄取随时间下降而fILD靶本比稳定,68Ga-FAPI摄取与CT纤维化指数正相关,人活检与小鼠肺组织免疫组化示FAP在纤维化病灶呈斑片状表达。

要点

  • 68Ga-FAPI PET/CT可显示fILD病灶与肺癌的高摄取及高靶本比。
  • 动态显像示fILD与LC时间-活动曲线不同,fILD靶本比稳定。
  • 68Ga-FAPI摄取与CT纤维化指数正相关,FAP在纤维化病灶斑片状表达。

核心结论

  • 68Ga-FAPI PET/CT成像是fILD与肺癌有前景的新型显像方法。
  • 其用于fILD监测与疗效评估的潜在临床价值需未来研究探讨。

研究设计与样本

  • 探索性研究纳入15例fILD并疑似肺癌患者,注射150-250 MBq 68Ga标记FAPI示踪剂FAPI-46后于10、60、180分钟采集PET,其中3例以40分钟动态扫描替代10分钟显像。
  • 测量纤维化病灶与肺癌的SUVmax与SUVmean并行CT密度校正,计算靶本比(TBR),PET与基于CT的纤维化评分相关分析,分析动态显像时间-活动曲线。
  • 对4例人fILD活检样本及Nedd4-2-/-小鼠纤维化肺行FAP免疫组化。

主要发现

  • fILD病灶与LC均示68Ga-FAPI摄取明显升高,注射后60分钟密度校正SUVmax与SUVmean分别为fILD 11.12 ± 6.71与4.29 ± 1.61、LC 16.69 ± 9.35与6.44 ± 3.29。
  • 注射后60分钟密度校正SUVmax与SUVmean的TBR分别为fILD 2.30 ± 1.47与1.67 ± 0.79、LC 3.90 ± 2.36与2.37 ± 1.14。
  • SUVmax与SUVmean随时间下降,fILD的TBR稳定而LC的TBR呈升高趋势。
  • 动态显像示fILD与LC的时间-活动曲线不同。
  • 68Ga-FAPI摄取与基于CT的纤维化指数呈正相关。

临床怎么用

  • 68Ga-FAPI PET/CT可用于同时显示fILD纤维化病灶与疑似肺癌病灶。
  • 动态显像时间-活动曲线可辅助区分fILD与肺癌摄取特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Interstitial lung diseases (ILDs) comprise over 200 parenchymal lung disorders. Among them, fibrosing ILDs, especially idiopathic pulmonary fibrosis, are associated with a poor prognosis, whereas some other ILDs, such as sarcoidosis, have a much better prognosis. A high proportion manifests as fibrotic ILD (fILD). Lung cancer (LC) is a frequent complication of fILD. Activated fibroblasts are crucial for fibrotic processes in fILD. The aim of this exploratory study was to evaluate the imaging properties of static and dynamic fibroblast activation protein (FAP) inhibitor (FAPI) PET/CT in various types of fILD and to confirm FAP expression in fILD lesions by FAP immunohistochemistry of human fILD biopsy samples and of lung sections of genetically engineered (Nedd4-2-/- ) mice with an idiopathic pulmonary fibrosislike lung disease. Methods: PET scans of 15 patients with fILD and suspected LC were acquired 10, 60, and 180 min after the administration of 150-250 MBq of a 68Ga-labeled FAPI tracer (FAPI-46). In 3 patients, dynamic scans over 40 min were performed instead of imaging after 10 min. The SUVmax and SUVmean of fibrotic lesions and LC were measured and CT-density-corrected. Target-to-background ratios (TBRs) were calculated. PET imaging was correlated with CT-based fibrosis scores. Time-activity curves derived from dynamic imaging were analyzed. FAP immunohistochemistry of 4 human fILD biopsy samples and of fibrotic lungs of Nedd4-2-/- mice was performed. Results: fILD lesions as well as LC showed markedly elevated 68Ga-FAPI uptake (density-corrected SUVmax and SUVmean 60 min after injection: 11.12 ± 6.71 and 4.29 ± 1.61, respectively, for fILD lesions and 16.69 ± 9.35 and 6.44 ± 3.29, respectively, for LC) and high TBR (TBR of density-corrected SUVmax and SUVmean 60 min after injection: 2.30 ± 1.47 and 1.67 ± 0.79, respectively, for fILD and 3.90 ± 2.36 and 2.37 ± 1.14, respectively, for LC). SUVmax and SUVmean decreased over time, with a stable TBR for fILD and a trend toward an increasing TBR in LC. Dynamic imaging showed differing time-activity curves for fILD and LC. 68Ga-FAPI uptake showed a positive correlation with the CT-based fibrosis index. Immunohistochemistry of human biopsy samples and the lungs of Nedd4-2-/- mice showed a patchy expression of FAP in fibrotic lesions, preferentially in the transition zone to healthy lung parenchyma. Conclusion:68Ga-FAPI PET/CT imaging is a promising new imaging modality for fILD and LC. Its potential clinical value for monitoring and therapy evaluation of fILD should be investigated in future studies.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Röhrich M, Leitz D, Glatting FM, et al. Fibroblast Activation Protein-Specific PET/CT Imaging in Fibrotic Interstitial Lung Diseases and Lung Cancer: A Translational Exploratory Study. J Nucl Med. 2021. PMID: 34272325. doi:10.2967/jnumed.121.261925

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。